SCHEMBL9894869

SCHEMBL9894869

Cn1nnc(-c2ccc(F)cc2)c1C(=O)CBr

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.45
GABRA5 P31644 3/20 0.39
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
DHFR P00374 1/20 0.36
PTGER4 P35408 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RAB9A P51151 1/20 0.36
LPAR1 Q92633 1/20 0.36
MAPK14 Q16539 2/20 0.35
LMNA P02545 1/20 0.35
USP2 O75604 1/20 0.35
HSD17B10 Q99714 1/20 0.35
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9894641 0.83 PTGS2 (0.41) GABRA5ALDH1A1HPGDDHFRPTGER4
SCHEMBL28431605 0.79 SMN1; SMN2 (0.39) ALDH1A1HPGDSMN1; SMN2RAB9ALPAR1
SCHEMBL9895453 0.77 DHFR (0.38) ALDH1A1HPGDDHFRSMN1; SMN2RAB9A
SCHEMBL21834355 0.75 GABRA5 (0.40) GABRA5ALDH1A1SMN1; SMN2RAB9ALPAR1
SCHEMBL27933716 0.75 GABRA5 (0.39) PTPN1GABRA5ALDH1A1HPGDSMN1; SMN2
SCHEMBL9895828 0.72 HSD11B1 (0.41) ALDH1A1HPGDRAB9AHSD17B10TP53
SCHEMBL2687825 0.72 CSNK1D (0.43) GABRA5ALDH1A1RAB9ALPAR1MAPK14
SCHEMBL14711183 0.71 LPAR1 (0.48) PTPN1ALDH1A1HPGDSMN1; SMN2RAB9A
SCHEMBL25045153 0.71 NPC1 (0.45) GABRA5ALDH1A1RAB9AMAPK14
SCHEMBL27915201 0.71 GABRA5 (0.43) GABRA5ALDH1A1HPGDSMN1; SMN2LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649064-B1 NOVEL TRIAZOLE COMPOUNDS III HOFFMANN LA ROCHE (CH) 2019-10-02 EP disclosed
EP-2649064-A1 NOVEL TRIAZOLE COMPOUNDS III F. Hoffmann-La Roche AG (CH) 2013-10-16 EP disclosed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US disclosed
WO-2012076590-A1 NOVEL TRIAZOLE COMPOUNDS III F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 WO disclosed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS GABRA5, GABRA1, GABRB1 PTPN1 2453/4885GABRA5 1/4885ALDH1A1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.